Tisotumab vedotin

Leave a review
Bookmark
Share
Report
prev
next

Indicaton

Tisotumab vedotin (TV) is an investigational antibody-drug conjugate (ADC) designed to target the Tissue Factor antigen and is being developed in cervical cancer as well as other solid tumors.

Therapeutic indications

Oncology

Type of product

Antibody

Table

Phase

Phase II started
Partnering status

Partnered
Partner

Genmab A/S

You may also be interested in

3D CoSeedis in chip Assays

Preclinical 3D Study models for oncology and neurology.

Marketed

F2i

F2i is a first-in-class, non-kinase, protein-protein interaction inhibitor of aberrant fibroblast growth factor signalling pathway in invasive cancers

Discovery

MV-004

MV-004 is an orally available recombinant bacterial enzyme acting in the small intesine to adaptively modulate microbiota function during cancer immunotherapy. MV004 has been conceived to convert the majority of patients with solid tumors non-responding to immune checkpoint blockade (ICB) to responders.

Discovery